Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel
  • USA - English


News provided by

Wright & Schulte LLC

Sep 13, 2014, 00:00 ET

Share this article

Share toX

Share this article

Share toX

FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel
FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel

If your believe you have suffered cardiovascular problems due to Androgel, Testim, Androderm or other Testosterone Therapy Drugs Call Wright & Schulte today for a Free Legal Evaluation at 1-800-399-0795 or by visiting www.yourlegalhelp.com

Post this

Columbus, OH (PRWEB) September 13, 2014 -- As low testosterone lawsuit claims continue to increase, Wright & Schulte LLC notes two of the U.S. Food & Drug Administration (FDA) advisory committees will meet on September 17 and 18 to discuss controversial public health issues surrounding testosterone replacement therapy. The Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will tackle the issues of identifying the appropriate patient population for testosterone replacement therapy and the potential risk of major cardiovascular events associated with the use of such testosterone drugs as AndroGel, Androderm and Testim. Cardiovascular events, such as heart attacks, strokes, blood clots and death have been alleged in testosterone side-effects lawsuits that are pending in the U.S. District Court, Northern District of Illinois where they have been consolidated for pretrial proceedings. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545) As of August 15, there are 177 testosterone lawsuits pending against various testosterone manufacturers filed on behalf of men who contend that they have suffered injuries due to taking testosterone replacement medication.
[fda.gov/downloads/AdvisoryCommittees
/CommitteesMeetingMaterials/Drugs
/ReproductiveHealthDrugsAdvisoryCommittee
/UCM412536.pdf, August 22, 2014]
[jpml.uscourts.gov/sites/jpml/files
/Pending_MDL_Dockets_By_District-August-15-2014.pdf, August 15, 2014]

The firm continues to speak with men who believe they have suffered heart attacks or strokes after using testosterone therapy drugs. If you have experienced cardiac side-effects after taking "Low-T" drugs such as AndroGel, Androderm and Testim contact one of our attorneys for a free legal consultation by calling 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information on testosterone lawsuit claims.

According to background material the FDA prepared in advance of the meeting, the federal agency will ask its joint committees whether the available scientific evidence supports the benefits of testosterone treatment in the patients currently being treated for low testosterone. Panel members will also be asked for their opinion on whether there are potential cardiovascular risks attributable to testosterone therapy. If it is determined that there is a link between testosterone replacement medication and adverse cardiovascular events, the panel will be asked how best to further evaluate the cardiovascular risk. The FDA’s advisory committees provide expert advice to the federal agency on a range of complex issues, including questions related to the development and evaluation of
FDA-regulated products. According to the FDA, its advisory committees are a “valuable resource” and make important contributions to the agency’s decision-making processes.
[fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf, August 22, 2014]
[fda.gov/ForConsumers/ConsumerUpdates/ucm048040.htm, December 7, 2013]

The FDA said its rationale for convening the meeting is based on the agency's re-evaluation of FDA-approved prescription testosterone products, such as Depo-Testosterone, Axiron, and Delatestryl. In January, the FDA announced that after reviewing two studies, it was launching an investigation into drugs used to treat hypoganadism, which is low testosterone levels in men due to an underlying medical condition. The first study published in the November 2013 Journal of the American Medical Association, found that older men who had underlying cardiovascular disease and took low testosterone treatment had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take the low testosterone medication. The second study published in the PLOS One Journal on January 29, 2014, found that men over 65 and younger men with a pre-existing heart disease were at a greater risk of having a heart attack within the first 90 days after taking low testosterone drugs for the first time. [fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014] [plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014] [jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]

In another action related to regulation of testosterone replacement therapy drugs, the FDA in June ordered manufactuers of all FDA-approved testosterone replacement therapy medications to include a general warning on their drug labels about the risk of blood clots developing in veins as a result of using low testosterone treatment medication. Testosterone drug labels already had a warning about venous blood clots as a result of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment. According to the FDA, post-market reports showed blood clots are occurring that are unrelated to polycythemia.
[fda.gov/drugs/drugsafety/ucm401746.htm, June 19, 2014]

Court records indicate that a Case Management Conference for testosterone lawsuit claims (MDL 2545) was held in August in which attorneys for plaintiffs and defendants discussed procedures for the discovery phase of the testosterone litigation pending in the Northern Illinois federal court. The parties also discussed collaborating with state courts that are handling testosterone litigation. The Philadelphia Court of Common Pleas is one state court in which a testosterone lawsuit was filed. In May 8, a testosterone claimed was filed on behalf of a Georgia man who alleges that he suffered a heart attack as a result of using Fortesta testosterone gel. (Taylor et al v. Endo Pharmaceuticals Inc., Case number 140500775) The testosterone lawsuit purports that the defendants, Endo Pharmaceuticals Inc. and Prostrakan Group PLC, which markets and manufactures Fortesta, knew about the dangers associated with the testosterone gel, but failed to disclose the risk of heart attacks and other cardiovascular problems associated with taking the testosterone treatment drug.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free low testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.